Do you want to read an article? Please log in or register.
Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials
Gynecologic Cancer
Related content
Breast Cancer
Recent Developments in Metastatic Breast Cancer
healthbook TIMES Oncology Hematology
RECOMMENDED
Gynecologic Cancer
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status
Cancer Treat Rev.
Tomao F, Bardhi E, Di Pinto A, Sassu CM, Biagioli E, Petrella MC, Palaia I, Muzii L, Colombo N, Panici PB
doi: 10.1016/j.ctrv.2019.101909.
COMMENTED
Gastrointestinal Cancer
Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial
★ 3
Recommended and commented by
PD Dr Sara De Dosso, Faculty Member
J Clin Oncol
Kanemitsu Y, Shimizu Y, Mizusawa J, Inaba Y, Hamaguchi T, Shida D, Ohue M, Komori K, Shiomi A, Shiozawa M, Watanabe J, Suto T, Kinugasa Y, Takii Y, Bando H, Kobatake T, Inomata M, Shimada Y, Katayama H, Fukuda H, JCOG Colorectal Cancer Study Group.
doi: 10.1200/JCO.21.01032
RECOMMENDED
Breast Cancer
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
Clin Cancer Res.
Mittendorf EA, Lu B, Melisko M, Price Hiller J, Bondarenko I, Brunt AM, Sergii G, Petrakova K, Peoples GE
doi: 10.1158/1078-0432.CCR-18-2867
Genitourinary Cancer
Use of First-Line PARP Inhibitors in Ovarian Cancer
healthbook TIMES Oncology Hematology
Hasler-Strub U.
doi: 10.36000/hbT.OH.2019.02.006
Breast Cancer
Effect of acupuncture on aromatase inhibitor-induced arthralgia in patients with breast cancer: A meta-analysis of randomized controlled trials
Breast.
Chen L, Lin CC, Huang TW, Kuan YC, Huang YH, Chen HC, Kao CY, Su CM, Tam KW
doi: 10.1016/j.breast.2017.03.015.
Lung, Respiratory and Thoracic Cancer
The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials
Eur J Cancer
Fujiwara Y, Horita N, Namkoong H, Galsky MD
doi: 10.1016/j.ejca.2021.03.012
RECOMMENDED
Gynecologic Cancer
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
J Clin Oncol
Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, Myers T, Taskiran C, Robison K, Mäenpää J, Willmott L, Colombo N, Thomes-Pepin J, Liontos M, Gold MA, Garcia Y, Sharma SK, Darus CJ, Aghajanian C, Okamoto A, Wu X, Safin R, Wu F, Molinero L, Maiya V, Khor VK, Lin YG, Pignata S
doi: 10.1200/JCO.21.00306
Gynecologic Cancer
The forefront of ovarian cancer therapy: update on PARP inhibitors
Ann Oncol.
Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, Pignata S
doi: 10.1016/j.annonc.